Niremia Collective Research
Investment Thesis
Niremia Collective is an early-stage venture fund investing in technology that drives innovation in mental, emotional, and social health (MESH). The firm's stated mission is "unlocking human potential through technology to enhance health, happiness, and personal growth," targeting the broader $8.5 trillion global wellness and wellbeing market. Niremia organizes its focus areas into six internal frameworks: VITAL, MESH, PEAK, SYNC, SOUL, and CITY, spanning mental health technology, workplace wellbeing solutions, aging/longevity, urban design, food tech, and women's health. The firm positions itself as a category specialist rather than a generalist, pairing capital with access to TransformativeTech, a global wellbeing-tech ecosystem with roughly 9,000 members across 72 countries that the co-founders also run.
Stage Focus
Niremia invests at pre-seed and seed stage. The firm's debut fund (closed February 2024) was explicitly structured around backing founders at the earliest, highest-risk stage of company formation in the wellbeing-tech category.
Check Size
Check size is not publicly disclosed on the firm's website, in press coverage, or in third-party investor databases reviewed. Given a $22.5M debut fund deploying across a 12+ (and growing, now 20+) company portfolio at pre-seed/seed, typical checks are likely in the low-to-mid six figures, but this is an inference, not a confirmed figure — no numeric check size fields are populated in the submitted payload.
Lead Tendency
Not disclosed in available sources. No press release or portfolio-company announcement reviewed identified Niremia as lead investor versus a participating investor, so lead tendency is submitted as "unknown."
Recent Activity
Niremia closed its $22.5M debut fund in February 2024, backed by LPs including Mistletoe Venture Partners, Shionogi Pharmaceuticals, MIXI Inc., and other domestic and international corporate/institutional investors. Since the close, the firm has continued to build out its portfolio (now 20+ companies visible on its site, versus 12 at fund close) and its advisory bench:
- June 2025: Appointed Hiroaki Kitano, Chief Technology Fellow at Sony Group and former Sony CTO, as Senior Executive Advisor.
- October 2024: Portfolio company Holobiome closed an oversubscribed seed round for its gut-brain-axis microbiome platform.
- September 2024: Portfolio company DeepWell DTx received FDA clearance for games and interactive media designed to treat mental health conditions — a notable regulatory milestone for a digital therapeutics portfolio company.
- September 2024: Co-founder Nichol Bradford was featured in Oprah Daily on longevity indicators, part of a broader pattern of the founders acting as media voices for the wellbeing-tech category.
- January 2024: Niremia was appointed an official ambassador for the SusHI Tech Tokyo 2024 Global Startup Program, consistent with the firm's cross-border US-Japan/Asia orientation.
Fund status reads as actively deploying: the portfolio has grown from 12 to 20+ named companies since the fund's February 2024 close, and the firm added a senior advisor as recently as mid-2025.
Portfolio Highlights
Niremia's public portfolio (30+ investments referenced site-wide, 20+ named) spans digital therapeutics, biotech/microbiome, sleep and recovery tech, oral health, and mental-health-focused consumer products:
- DeepWell DTx — video-game-based mental health therapeutics; received FDA clearance in September 2024.
- Holobiome — gut-brain-axis microbiome platform; closed an oversubscribed seed round in October 2024.
- Feno — AI-powered oral care and salivary microbiome testing.
- Apollo Neuro — wearable neuroscience-backed stress-relief device.
- Tripp — VR/XR wellness and mindfulness platform.
- Breathwrk — breathwork and guided-breathing consumer app.
- Ozlo Sleep — audio technology (Ozlo Sleepbuds) for sleep quality, founded by ex-Bose engineers.
- Other named portfolio companies: Allia Health, Awear, Complex Chaos, Enara Health, Feel Therapeutics, Galen AI, Hello Biome, Instill AI, Jona Health, MedMain, Metabolic Psychiatry Labs, Oral Genome, Piramidal, Skillprint, VizualizeMe, Wellset, Xspan.
No exits (acquisitions/IPOs) were identified in the sources reviewed; DeepWell DTx's FDA clearance is the most significant portfolio milestone found.
Team
- Naoko Okumoto — Co-founder, Managing Partner. Leads investment strategy and global wellbeing community building. 17 years at large tech companies; previously managed U.S. investments for Mistletoe Venture Partners; former CEO of Amber Bridge Partners, a cross-border business advisory firm.
- Nichol Bradford — Co-founder, Partner. Also Co-Founder and Executive Director of TransformativeTech.org, a global wellbeing-tech ecosystem (~9,000 members, 72 countries). Background at Disney Interactive and Vivendi Games; was part of the deal team on the Activision Blizzard–Microsoft merger.
- Hiroaki Kitano — Senior Executive Advisor. Chief Technology Fellow at Sony Group Corporation; served as Sony's CTO and Senior Executive VP (2022–2024) and CTO and Executive Deputy President (2024–2025).
- Rene Caissie — Senior Advisor. Entrepreneur, researcher, and former surgeon; CEO and Co-Founder of Medeloop.ai, an AI platform for clinical research and trials.
Decision Process
Not explicitly disclosed. With two co-founders holding Managing Partner / Partner titles and a small senior-advisor bench, the fund reads as a small-partnership structure rather than a solo-GP or formal investment-committee process, though this is inferred from team structure rather than confirmed directly.
Founder Preferences
Not explicitly stated in available sources. The firm's emphasis on "exclusive deal flow access," "evidence-based trend analysis," and leveraging the TransformativeTech ecosystem suggests a preference for founders embedded in or connected to the wellbeing-tech community, though this is inferred rather than sourced from a direct statement.
Geographic Focus
Headquartered in Palo Alto, California. The firm explicitly emphasizes bridging innovation between the US and Japan/Asia — reflected in Naoko Okumoto's Mistletoe Venture Partners background, the Japanese LP base (Shionogi Pharmaceuticals, MIXI Inc.), the SusHI Tech Tokyo ambassadorship, and the appointment of Sony's Hiroaki Kitano as senior advisor.